Comparative study on survival of patients with metastatic colorectal cancer treated with different molecular targeted drug delivery
10.3969/j.issn.1005-1678.2016.12.046
- VernacularTitle:不同分子靶向药物给药方案治疗转移性结直肠癌患者生存对比研究
- Author:
Cheng WANG
;
Li WANG
;
Huifeng WANG
- Keywords:
drug targeting;
metastatic colorectal cancer;
bevacizumab;
regimen;
survival
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(12):160-163
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study bevacizumab combined with chemotherapy regimen in treatment of different metastasis survival in patients with colorectal cancer, in order to optimize the scheme selection of bevacizumab for metastatic colorectal cancer metastasis , improve survival and quality of life of patients with rectal cancer.Methods 128 cases of late January 2013~2013 year in June in general hospital of medical university for treatment of metastatic colorectal cancer patients as the research object, which were randomLy divided into A, B, C, D 4 groups, 32 cases in each group, respectively with bevacizumab (5 mg/kg) combined with FOLFIRI and bevacizumab (10 mg/kg) combined with FOLFIRI and bevacizumab (5 mg/kg) combined with FOLFOX and bevacizumab ( 10 mg/kg ) therapy combined with FOLFIRI regimen, four patients underwent 6 cycles of treatment.Comparison of four groups of patients with recent clinical efficacy, progression free survival (survival progression-free, PFS), three years survival rate, overall survival (overall survival, OS).Results Four groups of patients with gender, age, stage of disease, ECOG score before treatment, primary tumor site, tumor metastasis, metastasis tumor diameter, there were no significant differences.Toxicity of different degrees occurred in the four groups during treatment, but the patients tolerated and complete the established chemotherapy.A, B, C, D group total effective rate were 56.25%, 59.38%, 46.88%, 50%, 3 years survival rates were 25%, 18.75%, 28.13%, 18.75%, PFS respectively: (9.5 ±1.1), (9.6 ±1.1), (9.2 ±1), (9.3 ± 0.9) months, overall survival were: (30.23 ±2.26), (29.83 ±2.24), (26.94 ±2.08), (27.19 ±2.11) months.A, B group of patients in the clinical total effective rate, three years survival rate were higher than that of C and D two groups, but there were no statistically significant difference between the two groups.A, DFS and TTP in B group were significantly higher than that of C and D two groups, and there were significant differences among the groups (P all <0.05), the difference between the two groups was no statistically significant, C, D between the two groups there was no significant difference, A, B groups were significantly higher than that of C, OS in D two group, and the difference between the two groups were statistically the significance (P<0.05), A, B between the two groups, but no significant difference, C, D between the two groups there was no significant difference.Conclusion according to the 5-10 mg/kg/m2 of bevacizumab combined with FOLFIRI regimen in the treatment of metastatic colorectal cancer, can effectively improve progression free survival in patients with a high clinical value to promote the transfer of clinical overall survival of patients with colorectal cancer.
